November 4, 2025
SAN MATEO, Calif. — November 4, 2025 — Leads & Copy — Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced its third-quarter 2025 financial results and provided a business update, reporting $133.0 million in global net product sales. Full-year revenue guidance is projected at $500 to $510 million.
According to Chris Peetz, Chief Executive Officer of Mirum, the company is well-positioned for 2026 with strong commercial momentum and multiple upcoming catalysts. Key progress includes completing enrollment in the VISTAS PSC study, maintaining momentum in VANTAGE and EXPAND, and initiating a Phase 2 study in Fragile X Syndrome.
Third quarter 2025 LIVMARLI net product sales reached $92.2 million, a 56% increase over third quarter 2024. Bile Acid Medicines third quarter net product sales were $40.8 million, a 31% increase over the previous year.
The Volixibat VISTAS study in primary sclerosing cholangitis (PSC) has completed enrollment, with topline data expected in the second quarter of 2026. Enrollment in the Volixibat VANTAGE study in primary biliary cholangitis (PBC) is expected to be completed in 2026, with topline data expected in the first half of 2027. The LIVMARLI EXPAND Phase 3 study for pruritus in rare cholestatic conditions is also expected to complete enrollment in 2026, with topline data expected in the first half of 2027.
Total revenue for the quarter ended September 30, 2025, was $133.0 million, compared to $90.4 million for the same period in 2024. As of September 30, 2025, Mirum had $378.0 million in unrestricted cash, cash equivalents, and investments, compared to $292.8 million as of December 31, 2024.
Mirum will host a conference call today, November 4th at 1:30 p.m. PT/4:30 p.m. ET, to provide business updates. The call can be accessed using the following details: US/Toll-Free: +1 833 470 1428, International: +1 646 844 6383, Access Code: 299722.
To learn more about Mirum, visit mirumpharma.com.
Source: Mirum Pharmaceuticals, Inc.
